Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell vaccine (Masonic Cancer Center)
- Development stage
- Unknown
- Lead developer
- Masonic Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
This autologous dendritic cell vaccine is an investigational immunotherapy developed by the Masonic Cancer Center at the University of Minnesota for the treatment of recurrent malignant brain tumors, including glioblastoma multiforme, medulloblastoma, and ependymoma. The vaccine is produced by harvesting a patient's own dendritic cells and loading them with antigens derived from allogeneic brain tumor stem cells. This approach aims to train the patient's immune system to specifically target and destroy cancer stem cells, which are often responsible for treatment resistance and recurrence. In clinical trials, the vaccine is administered intradermally, frequently in combination with imiquimod, a Toll-like receptor 7 (TLR7) agonist, to enhance the maturation and migration of the dendritic cells to local lymph nodes and stimulate a robust anti-tumor T-cell response.
- Other names
- Dendritic Cells Loaded With Brain Tumor Stem CellsDC Vaccine for Recurrent Malignant Gliomas
02
Targets
TLR7 (Toll-like receptor 7)TLR8 (Toll-like receptor 8)
Beyond the preview
Go deeper on autologous dendritic cell vaccine (Masonic Cancer Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell vaccine (Masonic Cancer Center).